NMDA receptor gene variations as modifiers in Huntington disease: a replication study

July 11, 2011 · Genetics

Carsten Saft, Jorgtepplen, Stefan Wieczorek, G. Bernhard Landwehrmeyer, Raymund A.C. Roos, Justo Garcia de Yebenes, Matthias Dose, Sarah J Tabrizi, David Craufurd, the REGISTRY investigators of the European Huntington's Disease Network Larissa Arning


Abstract

Several candidate modifier genes which, in addition to the pathogenic CAG repeat expansion, influence the age at onset (AO) in Huntington disease (HD) have already been described. The aim of this study was to replicate association of variations in the N-methyl D-aspartate receptor subtype genes GRIN2A and GRIN2B in the “REGISTRY” cohort from the European Huntington Disease Network (EHDN). The analyses did replicate the association reported between the GRIN2A rs2650427 variation and AO in the entire cohort. Yet, when subjects were stratified by AO subtypes, we found nominally significant evidence for an association of the GRIN2A rs1969060 variation and the GRIN2B rs1806201 variation. These findings further implicate the N-methyl D-aspartate receptor subtype genes as loci containing variation associated with AO in HD.

Introduction

Huntington disease (HD) is an autosomal dominant neurodegenerative disorder characterised by motor disturbances, cognitive decline, and neuropsychiatric symptoms. It is caused by a CAG repeat expansion (>36 repeats) in exon 1 of the HTT gene. [1] The lengths of the expanded CAG tract is inversely related to the age at clinical onset of HD, accounting for more than half of the overall variance in age at onset (AO). [2] Despite this strong correlation, there remains considerable variation of over 40 years in AO in individuals with identical repeat lengths. Several candidate modifier genes of HD have already been described in independent studies. [3] [4] [5] [6] [7] [8] [9] In order to confirm the associations between modifier gene variations and AO, independent replication studies are compulsory. Here, we tested the primary hypothesis of an original study[4], that variations in the NR2A and NR2B glutamate receptor subunit genes (GRIN2A, GRIN2B) explain additional variance in AO for HD.

Methods

The study cohort comprised 1,211 individuals of European ancestry with HD collected by the EHDN “REGISTRY” study prior to October 14, 2008. “REGISTRY” is a multi-centre, multi-national observational study which aims to obtain natural history data on a wide spectrum of the European HD population (http://www.euro-hd.net/html/registry).[10] In order to test previously reported HD genetic modifiers in this cohort, HD patients with available data on age, sex, age at symptom onset, mutant CAG repeat size and body mass index (BMI) were included (initial n = 1211; n = 1069; 529 men and 540 women had a complete data set).

The expanded trinucleotide repeats ranged from 40 to 89 with a mean (± SD) of 45±4.7 CAGs, and AO ranged from 6 to 74 years, with an onset (mean ± SD) of 42 ±11.8 years. AO was defined as the age at which, according to the rater, the first signs of HD appeared. Five hundred and thirty-eight patients first presented with motor disturbances (mean ± SD motor AO = 43.4±11.6 years), 241 with psychiatric problems (mean ± SD psychiatric AO = 39.9±10.8 years), and 112 with cognitive decline (mean ± SD cognitive AO = 38.6±13.1 years). For the remaining patients no specific symptoms were listed (mean ± SD AO = 42.1±11.8 years). Genotyping of three SNPs was conducted as described before.[4]

Results

None of the SNPs deviated from Hardy – Weinberg Equilibrium (HWE). Considering the earliest AO (n = 1,069), we did find evidence of association of the GRIN2A SNP rs2650427 (table 1). The R² statistic rose modestly (from 0.634 to 0.635) but significantly (p=0.028) when GRIN2A genotypes were added to the regression model. The analysis did not, however, replicate the association reported between the SNP rs1969060 in intron 2 of the GRIN2A gene and SNP C2664T (rs1806201) in exon 12 of the GRIN2B gene (table 1); but when dividing the cohort according to the nature of the symptoms presented initially, both the GRIN2B C2664T and the GRIN2A rs1969060 polymorphisms explained a small but considerable amount of additional variance.
Interestingly, the association of cognitive AO (\( \text{rs1806201} \) + HD CAG 40-67 (\( n=241 \))) increased the \( R^2 \) statistic from 0.515 to 0.523 with the \( \text{GRIN2A} \) rs1969060 genotypes included (\( p=0.026 \), table 1).

### Table 1. Genotype-Specific Analysis

<table>
<thead>
<tr>
<th>Genotypes</th>
<th>CAG Mean ± SD</th>
<th>Motor AO Mean ± SD</th>
<th>R²*</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HD CAG 40-89 (( n=1069 ))</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+ ( \text{GRIN2B} ) C2664T (( rs1806201 ))</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC (n=560)</td>
<td>44.94±4.8</td>
<td>42.13±12.1</td>
<td>0.634</td>
<td>0.541</td>
</tr>
<tr>
<td>CT (n=436)</td>
<td>45.02±4.5</td>
<td>41.32±11.3</td>
<td>0.634</td>
<td>0.199</td>
</tr>
<tr>
<td>TT (n=73)</td>
<td>44.86±4.6</td>
<td>43.14±11.9</td>
<td>0.634</td>
<td>0.196</td>
</tr>
<tr>
<td>additive</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+ ( \text{GRIN2A} ) rs1969060</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TT (n=745)</td>
<td>44.83±4.5</td>
<td>42.00±11.9</td>
<td>0.634</td>
<td>0.160</td>
</tr>
<tr>
<td>TC (n=292)</td>
<td>45.24±5.1</td>
<td>41.67±11.5</td>
<td>0.634</td>
<td>0.203</td>
</tr>
<tr>
<td>CC (n=32)</td>
<td>45.75±4.2</td>
<td>40.66±11.5</td>
<td>0.634</td>
<td>0.645</td>
</tr>
<tr>
<td>additive</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+ ( \text{GRIN2A} ) rs2650427</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC (n=374)</td>
<td>44.99±4.0</td>
<td>41.40±11.9</td>
<td>0.634</td>
<td>0.125</td>
</tr>
<tr>
<td>CT (n=512)</td>
<td>44.94±5.2</td>
<td>41.99±11.9</td>
<td>0.634</td>
<td>0.891</td>
</tr>
<tr>
<td>TT (n=183)</td>
<td>42.51±4.2</td>
<td>43.14±10.9</td>
<td>0.635</td>
<td>0.031</td>
</tr>
<tr>
<td>additive</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Genotypes</th>
<th>CAG Mean ± SD</th>
<th>Psychiatric AO Mean ± SD</th>
<th>R²*</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HD CAG 40-77 (( n=538 ))</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+ ( \text{GRIN2B} ) C2664T (( rs1806201 ))</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC (n=274)</td>
<td>44.52±3.8</td>
<td>44.41±11.8</td>
<td>0.622</td>
<td>0.099</td>
</tr>
<tr>
<td>CT (n=221)</td>
<td>44.96±4.1</td>
<td>41.98±11.1</td>
<td>0.623</td>
<td>0.046</td>
</tr>
<tr>
<td>TT (n=43)</td>
<td>44.77±4.9</td>
<td>44.07±12.4</td>
<td>0.620</td>
<td>0.560</td>
</tr>
<tr>
<td>additive</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+ ( \text{GRIN2A} ) rs1969060</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TT (n=373)</td>
<td>44.51±3.6</td>
<td>43.79±11.5</td>
<td>0.620</td>
<td>0.824</td>
</tr>
<tr>
<td>TC (n=153)</td>
<td>45.32±4.9</td>
<td>42.19±11.9</td>
<td>0.620</td>
<td>0.934</td>
</tr>
<tr>
<td>CC (n=12)</td>
<td>43.75±2.5</td>
<td>46.25±9.5</td>
<td>0.620</td>
<td>0.658</td>
</tr>
<tr>
<td>additive</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+ ( \text{GRIN2A} ) rs2650427</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC (n=181)</td>
<td>44.15±3.8</td>
<td>41.99±11.8</td>
<td>0.620</td>
<td>0.362</td>
</tr>
<tr>
<td>CT (n=259)</td>
<td>44.48±4.1</td>
<td>44.00±11.9</td>
<td>0.620</td>
<td>0.792</td>
</tr>
<tr>
<td>TT (n=98)</td>
<td>44.60±4.2</td>
<td>44.34±10.4</td>
<td>0.621</td>
<td>0.143</td>
</tr>
<tr>
<td>additive</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Genotypes</th>
<th>CAG Mean ± SD</th>
<th>Psychiatric AO Mean ± SD</th>
<th>R²*</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HD CAG 40-67 (( n=241 ))</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+ ( \text{GRIN2B} ) C2664T (( rs1806201 ))</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC (n=139)</td>
<td>44.81±4.4</td>
<td>39.50±11.3</td>
<td>0.513</td>
<td>0.964</td>
</tr>
<tr>
<td>CT (n=90)</td>
<td>44.74±3.8</td>
<td>39.79±10.5</td>
<td>0.514</td>
<td>0.607</td>
</tr>
<tr>
<td>TT (n=12)</td>
<td>43.67±2.1</td>
<td>44.58±9.6</td>
<td>0.517</td>
<td>0.211</td>
</tr>
<tr>
<td>additive</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+ ( \text{GRIN2A} ) rs1969060</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TT (n=172)</td>
<td>44.79±4.1</td>
<td>39.01±10.9</td>
<td>0.523</td>
<td>0.026</td>
</tr>
<tr>
<td>TC (n=63)</td>
<td>44.01±3.7</td>
<td>42.78±9.8</td>
<td>0.523</td>
<td>0.033</td>
</tr>
</tbody>
</table>
In order to reduce heterogeneity, and to facilitate the discovery of clinically relevant biological pathways.

emphasizing the need for stringent statistical thresholds. On the other hand, since linkage disequilibrium is not uniform across

The failure to replicate the sex-specific effect of rs1806201 suggests that the original observation may have been false positive,

yet, the interpretation of the association of cognitive AO with the GRIN2A rs2650427 polymorphism should be considered with

care since the sample size of this subgroub (n=112) is too small to provide the statistical power required.

Yet, the interpretation of the association of cognitive AO with the GRIN2A rs2650427 polymorphism should be considered with

care since the sample size of this subgroub (n=112) is too small to provide the statistical power required.

Unfortunately, none of the SNPs associated has been validated functionally and it is most likely that the polymorphisms

analysed are not the functional variations, but represent markers in linkage disequilibrium with variations that modify the AO.

Table 1 The variability in AO attributable to the CAG repeat length was assessed by linear regression using the logarithmically transformed AO as the dependent variable and GRIN genotypes as independent variables. *R² illustrates the relative improvement of the regression model, when the genotypes are considered in addition to the CAG repeats.

In order to control the effect of sex-specific associations, we further analysed each combination of genotype with sex, but there was no trend towards significance. Moreover, on average, psychiatric and cognitive symptoms significantly predate clinical motor onset by 3.5 and 4.8 years (p< 0.001), thus confirming that affective and cognitive symptoms could be early manifestations of neuronal dysfunction.

Discussion

Of the three polymorphisms tested, GRIN2A rs2650427 showed the most consistent evidence of replication in the EHDN Registry study sample. This is in accordance with another replication study in the large set of kindreds from Venezuela, where GRIN2A variation also explained a small but considerable amount of additional variance in residual AO.[5]

Yet, the interpretation of the association of cognitive AO with the GRIN2A rs2650427 polymorphism should be considered with caution since the sample size of this subgroub (n=112) is too small to provide the statistical power required.

Unfortunately, none of the SNPs associated has been validated functionally and it is most likely that the polymorphisms analysed are not the functional variations, but represent markers in linkage disequilibrium with variations that modify the AO.

Although, synonymous SNPs like GRIN2B rs1806201 might be pathogenetically relevant via influencing mRNA splicing, protein stability and structure.

The failure to replicate the sex-specific effect of rs1806201 suggests that the original observation may have been false positive, emphasizing the need for stringent statistical thresholds. On the other hand, since linkage disequilibrium is not uniform across populations, the mixed ancestry in the EHDN REGISTRY study sample could account for heterogeneous results. Inconsistent results may also occur because of difficulties in exact AO definitions. The data stresses the need for precise phenotyping in order to reduce heterogeneity, and to facilitate the discovery of clinically relevant biological pathways.
Although the associations replicated explain only a small fraction of the variance of AO, the observed correlations with HD phenotypes demonstrate that GRIN2A and GRIN2B remain promising candidate genes, worth to be studied further in more detail.

Acknowledgments

The authors thank all EHDN Registry Study Group investigators for collecting the data and all participating patients for their time and efforts.

Correspondence to Dr Larissa Arning, Ruhr-University, Department of Human Genetics, Universitätsstr. 150, MA5/39, 44801 Bochum, Germany, larissa.arning@rub.de

Competing interests

The authors have declared that no competing interests exist.

Funding information

The European Huntington’s Disease Network is funded by CHDI Foundation, Inc. CS was supported by FoRUM grant K040-09.

Ethics approval

This study was conducted with the approval of the local ethics committee of the different clinical centres.

Expansion of Collaborator List

Investigators of the European Huntington’s Disease Network

K Barth, Language coordinator
M Bascuñana Garde, Language coordinator
R Bos, Language coordinator
D Ecker, Language coordinator
OJ Handley, Language coordinator
N Heinonen, Language coordinator
C Held, Language coordinator
M Laurà, Language coordinator
A Martínez Descals, Language coordinator
T Mestre, Language coordinator
D Monza, Language coordinator
J Najì, Language coordinator
M Orth, Language coordinator
H Padieu, Language coordinator
S Pro Koivisto, Language coordinator
A Rialland, Language coordinator
P Sasinková, Language coordinator
P Trigo Cubillo, Language coordinator
M van Walsem, Language coordinator
Barbara Vives, Hospital Son Dureta, Palma, Spain
Fátima Carrillo, Hospital Virgen del Rocío, Sevilla, Spain
Pablo Mir, Hospital Virgen del Rocío, Sevilla, Spain
María José Lama Suarez, Hospital Virgen del Rocío, Sevilla, Spain
Ghada Louifi, Norrlands Universitet Sjukhus, Department of Neurology, Umeå, Sweden
Eva-Lena Stattin, Norrlands Universitet Sjukhus, Department of Neurology, Umeå, Sweden
Laila Westman, Norrlands Universitet Sjukhus, Department of Neurology, Umeå, Sweden
Birgitta Wikström, Norrlands Universitet Sjukhus, Department of Neurology, Umeå, Sweden
Sven Pålhagen, Karolinska-University Hospital, Stockholm, Sweden
Elisabeth Björnsson, Karolinska-University Hospital, Stockholm, Sweden
Jean-Marc Burgunder, Neurologische Klinik des Inselspitals, Bern, Switzerland
Irene Romero, Zentrum für Bewegungsstörungen, Neurologische Klinik und Poliklinik, Bern, Switzerland
Michael Schüpbach, Zentrum für Bewegungsstörungen, Neurologische Klinik und Poliklinik, Bern, Switzerland
Sabine Weber Zaugg, Zentrum für Bewegungsstörungen, Neurologische Klinik und Poliklinik, Bern, Switzerland
Monique S.E. van Hout, Medisch Spectrum Twente, Ensched, The Netherlands
Jeroen P.P. van Vugt, Medisch Spectrum Twente, Ensched, The Netherlands
A. Marit de Weert, Medisch Spectrum Twente, Ensched, The Netherlands
J.J.W. Bolwijn, Polikliniek Neurologie, Groningen, The Netherlands
M. Dekker, Polikliniek Neurologie, Groningen, The Netherlands
K.L. Leenders, Polikliniek Neurologie, Groningen, The Netherlands
J.C.H. van Oostrom, Polikliniek Neurologie, Groningen, The Netherlands
Reineke Bos, Leiden University Medical Centre, Leiden, The Netherlands
Eve M. Dumas, Leiden University Medical Centre, Leiden, The Netherlands
Caroline K. Jurgens, Leiden University Medical Centre, Leiden, The Netherlands
Simon J. A. van den Bogaard, Leiden University Medical Centre, Leiden, The Netherlands
Raymund A.C. Roos, Leiden University Medical Centre, Leiden, The Netherlands
Marie-Noëlle Witjes-Ané, Leiden University Medical Centre, Leiden, The Netherlands
Berry Kremer, Universitair Medisch Centrum St. Radboud, Neurology, Nijmegen, The Netherlands
C.C.P. Verstappen, Universitair Medisch Centrum St. Radboud, Neurology, Nijmegen, The Netherlands
Jenny de Souza, The Barberry Centre, Dept of Psychiatry, Birmingham, UK
Hugh Rickards, The Barberry Centre, Dept of Psychiatry, Birmingham, UK
Jan Wright, The Barberry Centre, Dept of Psychiatry, Birmingham, UK
Roger A. Barker, Cambridge Centre for Brain Repair, Forvie Site, Cambridge, UK
Kate Fisher, Cambridge Centre for Brain Repair, Forvie Site, Cambridge, UK
Anna Olivia Goyder Goodman, Cambridge Centre for Brain Repair, Forvie Site, Cambridge, UK
Susan Hill, Cambridge Centre for Brain Repair, Forvie Site, Cambridge, UK
Ann Kershaw, Cambridge Centre for Brain Repair, Forvie Site, Cambridge, UK
Sarah Mason, Cambridge Centre for Brain Repair, Forvie Site, Cambridge, UK
References


